Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). PSAI segment includes the Company's business of manufacturing and marketing active pharmaceutical ingredients and intermediates (API) or bulk drugs. Proprietary Products segment focuses on the research, development and manufacture of differentiated formulations and new chemical entities. These products fall within the dermatology and neurology therapeutic areas, and are marketed and sold through its subsidiary, Promius Pharma, LLC.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals
- Sub-Industry: N/A
- Symbol: NYSE:RDY
- CUSIP: N/A
- Web: www.drreddys.com
Capitalization:- Market Cap: $5.92 billion
- Outstanding Shares: 165,801,000
Average Prices:- 50 Day Moving Avg: $32.97
- 200 Day Moving Avg: $38.79
- 52 Week Range: $29.83 - $50.10
P/E:- Trailing P/E Ratio: 32.21
- Foreward P/E Ratio: 19.71
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $2.2 billion
- Price / Sales: 2.69
- Book Value: $11.66 per share
- Price / Book: 3.06
Dividend:- Annual Dividend: $0.29
- Dividend Yield: 0.9%
Profitability:- EBIDTA: $386.11 million
- Net Margins: 7.92%
- Return on Equity: 9.27%
- Return on Assets: 5.06%
Debt:- Debt-to-Equity Ratio: 0.20%
- Current Ratio: 1.53%
- Quick Ratio: 1.10%
Misc:- Average Volume: 341,920 shs.
- Beta: 0.34
- Short Ratio: 12.2
Frequently Asked Questions for Dr. Reddy's Laboratories Ltd (NYSE:RDY)
What is Dr. Reddy's Laboratories Ltd's stock symbol?
Dr. Reddy's Laboratories Ltd trades on the New York Stock Exchange (NYSE) under the ticker symbol "RDY."
How often does Dr. Reddy's Laboratories Ltd pay dividends? What is the dividend yield for Dr. Reddy's Laboratories Ltd?
Dr. Reddy's Laboratories Ltd announced a None dividend on Friday, August 4th. Stockholders of record on Monday, July 17th will be paid a dividend of $0.294 per share on Thursday, August 10th. The ex-dividend date is Thursday, July 13th. View Dr. Reddy's Laboratories Ltd's Dividend History.
How were Dr. Reddy's Laboratories Ltd's earnings last quarter?
Dr. Reddy's Laboratories Ltd (NYSE:RDY) issued its earnings results on Tuesday, July, 26th. The company reported $0.00 EPS for the quarter. The company earned $479 million during the quarter, compared to analyst estimates of $557 million. Dr. Reddy's Laboratories Ltd had a return on equity of 9.27% and a net margin of 7.92%. View Dr. Reddy's Laboratories Ltd's Earnings History.
When will Dr. Reddy's Laboratories Ltd make its next earnings announcement?
Where is Dr. Reddy's Laboratories Ltd's stock going? Where will Dr. Reddy's Laboratories Ltd's stock price be in 2017?
3 equities research analysts have issued 12-month target prices for Dr. Reddy's Laboratories Ltd's stock. Their predictions range from $31.62 to $31.62. On average, they anticipate Dr. Reddy's Laboratories Ltd's stock price to reach $31.62 in the next year. View Analyst Ratings for Dr. Reddy's Laboratories Ltd.
Who are some of Dr. Reddy's Laboratories Ltd's key competitors?
Some companies that are related to Dr. Reddy's Laboratories Ltd include Patheon NV (PTHN), Catalent (CTLT), Valeant Pharmaceuticals International (VRX), Taro Pharmaceutical Industries (TARO), Akorn (AKRX), Opko Health (OPK), Hikma Pharmaceuticals Plc (HIK), BTG plc (BTG), Amicus Therapeutics (FOLD), Corcept Therapeutics Incorporated (CORT), Horizon Pharma PLC (HZNP), Theravance Biopharma (TBPH), Cambrex Corporation (CBM), AKCEA THERAPEUT (AKCA), Emergent Biosolutions (EBS), Impax Laboratories (IPXL), Innoviva (INVA) and Pacira Pharmaceuticals (PCRX).
Who are Dr. Reddy's Laboratories Ltd's key executives?
Dr. Reddy's Laboratories Ltd's management team includes the folowing people:
- Satish K. Reddy, Chairman of the Board
- G. V. Prasad, Co-Chairman of the Board, Chief Executive Officer, Managing Director
- Saumen Chakraborty, President, Chief Financial Officer, Global Head - HR and IT & BPE
- Sripada Chandrasekhar Ph.D., President, Global Head - Human Resources
- Abhijit Mukherjee, Chief Operating Officer
- Amit Biswas, Executive Vice President and Head - Integrated Product Development
- Raghav Chari, Executive Vice President and Head - Proprietary Products
- Samiran Das, Executive Vice President and Head - Global Manufacturing Operations
- M. V. Ramana, Executive Vice President and Head-Branded Markets - India & Emerging Markets
- Cartikeya Reddy, Executive Vice President and Head-Biologics
Who owns Dr. Reddy's Laboratories Ltd stock?
Dr. Reddy's Laboratories Ltd's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Fisher Asset Management LLC (3.38%), Royal Bank of Canada (2.09%), Commonwealth Bank of Australia (2.08%), Vanguard Group Inc. (0.89%), State Street Corp (0.38%) and Dimensional Fund Advisors LP (0.35%). View Institutional Ownership Trends for Dr. Reddy's Laboratories Ltd.
Who sold Dr. Reddy's Laboratories Ltd stock? Who is selling Dr. Reddy's Laboratories Ltd stock?
Dr. Reddy's Laboratories Ltd's stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., JPMorgan Chase & Co., US Bancorp DE, LMR Partners LLP, Acadian Asset Management LLC, Russell Investments Group Ltd., OxFORD Asset Management LLP and Schroder Investment Management Group. View Insider Buying and Selling for Dr. Reddy's Laboratories Ltd.
Who bought Dr. Reddy's Laboratories Ltd stock? Who is buying Dr. Reddy's Laboratories Ltd stock?
Dr. Reddy's Laboratories Ltd's stock was bought by a variety of institutional investors in the last quarter, including Royal Bank of Canada, First Trust Advisors LP, Commonwealth Bank of Australia, State Street Corp, Prudential Financial Inc., Segantii Capital Management Ltd, Fisher Asset Management LLC and Mitsubishi UFJ Trust & Banking Corp. View Insider Buying and Selling for Dr. Reddy's Laboratories Ltd.
How do I buy Dr. Reddy's Laboratories Ltd stock?
Shares of Dr. Reddy's Laboratories Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Dr. Reddy's Laboratories Ltd's stock price today?
One share of Dr. Reddy's Laboratories Ltd stock can currently be purchased for approximately $35.68.
MarketBeat Community Rating for Dr. Reddy's Laboratories Ltd (NYSE RDY)MarketBeat's community ratings are surveys of what our community members think about Dr. Reddy's Laboratories Ltd and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Dr. Reddy's Laboratories Ltd (NYSE:RDY) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 1 Hold Rating, 1 Buy Rating |
| Consensus Rating: | Hold (Score: 2.00) |
| Consensus Price Target: | $31.62 (11.38% downside) |
Analysts' Ratings History for Dr. Reddy's Laboratories Ltd (NYSE:RDY)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/3/2017 | Jefferies Group LLC | Reiterated Rating | Sell | $31.62 | Medium |  |
| 8/31/2017 | CLSA | Upgrade | Underperform -> Outperform | | High | |
| 5/15/2017 | Deutsche Bank AG | Upgrade | Sell -> Hold | | High | |
| 7/27/2016 | HSBC Holdings plc | Downgrade | Hold -> Reduce | | N/A | |
| 7/26/2016 | Credit Suisse Group | Downgrade | Neutral -> Underperform | | N/A | |
| 5/2/2016 | Goldman Sachs Group, Inc. (The) | Initiated Coverage | Neutral | | N/A | |
| 11/10/2015 | Citigroup Inc. | Downgrade | Buy -> Neutral | | N/A | |
| 11/6/2015 | Barclays PLC | Downgrade | Overweight -> Equal Weight | | N/A | |
(Data available from 9/20/2015 forward)
Earnings History for Dr. Reddy's Laboratories Ltd (NYSE:RDY)Earnings History by Quarter for Dr. Reddy's Laboratories Ltd (NYSE RDY)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/24/2017 | | | | | | | | |
| 7/26/2016 | Q117 | | $0.00 | $557.00 million | $479.00 million | View | Listen | |
| 5/12/2016 | Q416 | | $0.07 | $2.41 billion | $567.00 billion | View | Listen | |
| 2/9/2016 | Q316 | | $0.51 | $2.48 million | $599.00 million | View | N/A | |
| 10/29/2015 | Q116 | | $0.65 | $2.54 billion | $609.00 million | View | Listen | |
| 5/12/2015 | Q415 | | $0.49 | $559.00 million | $621.00 million | View | Listen | |
| 1/29/2015 | Q315 | | $0.53 | $561.00 million | $610.00 million | View | N/A | |
| 7/30/2014 | Q115 | | $0.54 | $474.00 million | $486.00 million | View | N/A | |
| 5/13/2014 | Q414 | $0.52 | $0.47 | $557.00 million | $580.00 million | View | N/A | |
| 2/11/2014 | Q314 | $0.45 | $0.59 | $558.20 million | $571.00 million | View | N/A | |
| 10/31/2013 | Q214 | $0.46 | $0.65 | $561.00 million | $537.00 million | View | N/A | |
| 7/30/2013 | Q413 | $0.43 | $0.40 | $551.40 million | $478.00 million | View | N/A | |
| 5/14/2013 | | | $0.60 | | | View | N/A | |
| 2/14/2013 | Q313 | | $0.40 | $505.00 million | $522.00 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Dr. Reddy's Laboratories Ltd (NYSE:RDY)Current Year EPS Consensus Estimate: $1.20 EPS
Next Year EPS Consensus Estimate: $1.81 EPS
Current Dividend Information for Dr. Reddy's Laboratories Ltd (NYSE:RDY)| Most Recent Dividend: | 8/10/2017 |
| Annual Dividend: | $0.29 |
| Dividend Yield: | 0.81% |
| Dividend Growth: | 7.40% (3 Year Average) |
| Payout Ratio: | 27.88% (Trailing 12 Months of Earnings)
24.17% (Based on This Year's Estimates)
16.02% (Based on Next Year's Estimates)
|
Dividend History by Quarter for Dr. Reddy's Laboratories Ltd (NYSE RDY)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 8/4/2017 | None | $0.29 | | 7/13/2017 | 7/17/2017 | 8/10/2017 |
| 6/6/2017 | | $0.29 | | 7/13/2017 | 7/17/2017 | 7/17/2017 |
| 6/6/2016 | Annual | $0.28 | | 7/14/2016 | 7/18/2016 | 7/18/2016 |
(Data available from 1/1/2013 forward)
Insider Trading History for Dr. Reddy's Laboratories Ltd (NYSE:RDY)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Dr. Reddy's Laboratories Ltd (NYSE:RDY)
Latest Headlines for Dr. Reddy's Laboratories Ltd (NYSE:RDY)
| Source: |
|
| Date | Headline |
|---|
 | SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Dr. Reddy's Laboratories Ltd. (RDY) & Lead Plaintiff Deadline - October 24, 2017
finance.yahoo.com - September 20 at 8:15 AM |
| Scott+Scott, Attorneys at Law, LLP Reminds Investors of October 24th Lead Plaintiff Deadline in Securities Class Action Against Dr. Reddy’s Laboratories Limited (RDY)
finance.yahoo.com - September 20 at 8:15 AM |
| INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Dr. Reddy's Laboratories Ltd. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 24, 2017 - RDY
finance.yahoo.com - September 20 at 8:15 AM |
| IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - September 20 at 8:15 AM |
| The Klein Law Firm Reminds Investors of Commencement of a Class Action Filed on Behalf of Dr. Reddy’s Laboratories Ltd. Shareholders and a Lead Plaintiff Deadline of October 24, 2017
finance.yahoo.com - September 19 at 7:05 AM |
 | Comparing Dr. Reddy's Laboratories (RDY) and Its Peers
www.americanbankingnews.com - September 18 at 4:30 PM |
 | RDY EQUITY ALERT: The Law Offices of Vincent Wong Reminds ... - Business Wire (press release)
www.businesswire.com - September 16 at 1:37 AM |
| EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Dr. Reddy’s Laboratories Limited and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - September 16 at 1:36 AM |
 | Mid-Afternoon Market Update: Dow Rises Over 50 Points; T2 Biosystems Shares Plummet - Benzinga
www.benzinga.com - September 15 at 3:30 PM |
| RDY EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Dr. Reddy’s Laboratories Ltd. and a Lead Plaintiff Deadline of October 24, 2017
finance.yahoo.com - September 15 at 3:30 PM |
| EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Dr. Reddy’s Laboratories Ltd. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of October ...
www.businesswire.com - September 15 at 8:04 AM |
| EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Dr. Reddy’s Laboratories Ltd. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 24, 2017
finance.yahoo.com - September 15 at 8:04 AM |
| EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - September 15 at 8:04 AM |
 | Form 6-K DR REDDYS LABORATORIES For: Sep 13 - StreetInsider.com
www.streetinsider.com - September 13 at 3:36 PM |
| RDY INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Dr. Reddy's ... - Business Wire (press release)
www.businesswire.com - September 13 at 3:36 PM |
| SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Dr. Reddy's Laboratories Ltd. (RDY) & Lead Plaintiff Deadline - October 24, 2017
finance.yahoo.com - September 13 at 3:35 PM |
| The Klein Law Firm Announces Commencement of a Class Action Filed on Behalf of Dr. Reddy’s Laboratories Ltd. Shareholders and a Lead Plaintiff Deadline of October 24, 2017
finance.yahoo.com - September 13 at 3:35 PM |
| INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - September 13 at 3:35 PM |
| The Klein Law Firm Announces a Class Action Filed on Behalf of Dr. Reddy’s Laboratories Ltd. Shareholders and a Lead Plaintiff Deadline of October 24, 2017 (RDY)
finance.yahoo.com - September 13 at 8:19 AM |
| SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - September 13 at 8:19 AM |
| RDY INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Dr. Reddy’s Laboratories Ltd. and a Lead Plaintiff Deadline of October 24, 2017
finance.yahoo.com - September 12 at 9:09 AM |
| SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Dr. Reddy’s Laboratories Limited and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - September 12 at 9:08 AM |
| RDY SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Dr. Reddy’s Laboratories Ltd. and a Lead Plaintiff Deadline of October 24, 2017
finance.yahoo.com - September 9 at 7:50 AM |
| Glancy Prongay & Murray LLP Continues Investigation on Behalf of Dr. Reddy’s Laboratories, Ltd. Investors
finance.yahoo.com - September 9 at 7:50 AM |
| DR. REDDY’S SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Dr. Reddy’s Laboratories Ltd. – (RDY)
finance.yahoo.com - September 9 at 7:50 AM |
| SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Dr. Reddy’s Laboratories Ltd. to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action Lawsuit
finance.yahoo.com - September 9 at 7:50 AM |
| INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - September 9 at 7:50 AM |
| DR. REDDY'S SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Dr. Reddy's Laboratories Ltd. – (RDY)
feeds.benzinga.com - September 8 at 11:57 PM |
| RDY SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Dr. Reddy's Laboratories Ltd. and a Lead Plaintiff Deadline of October 24, 2017
feeds.benzinga.com - September 8 at 3:41 PM |
| SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Dr. Reddy’s Laboratories Ltd. (RDY) & Lead Plaintiff Deadline: October 24, 2017
finance.yahoo.com - September 8 at 7:36 AM |
| IMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Dr. Reddy’s Laboratories Limited and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - September 8 at 7:36 AM |
| INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Dr. Reddy’s Laboratories Ltd. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 24, 2017
finance.yahoo.com - September 8 at 7:36 AM |
| IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Dr. Reddy’s Laboratories Limited and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - September 8 at 7:36 AM |
| Featured Company News - Dr. Reddy's Labs Announces the Launch of Anti-Depressant and Muscle Relaxant Tablets in the US
finance.yahoo.com - September 8 at 7:36 AM |
| IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited and Encourages Investors with Losses to Contact the Firm
feeds.benzinga.com - September 7 at 6:54 PM |
| IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - September 7 at 8:16 AM |
 | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Dr. Reddy's Laboratories Ltd. of a Class ... - GlobeNewswire (press release)
globenewswire.com - September 6 at 7:32 AM |
 | Dr. Reddy's Laboratories (RDY) Jumped After Court Ruling
www.rttnews.com - September 5 at 5:47 AM |
| Dr. Reddy's Laboratories' (RDY) "Sell" Rating Reaffirmed at Jefferies Group LLC
www.americanbankingnews.com - September 3 at 7:58 AM |
| IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Dr. Reddy's ... - Business Wire (press release)
www.businesswire.com - September 3 at 6:12 AM |
| Dr. Reddy's Laboratories Ltd (RDY) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - September 3 at 2:32 AM |
| The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Dr. Reddy’s Laboratories Ltd.
finance.yahoo.com - September 2 at 8:00 AM |
| DR. REDDY'S SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Dr. Reddy's Laboratories Ltd. - (RDY)
finance.yahoo.com - September 2 at 7:59 AM |
| IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Dr. Reddy’s Laboratories Limited and Encourages Investors With Losses to Contact the Firm
finance.yahoo.com - September 2 at 7:59 AM |
| SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Dr. Reddy's Laboratories Ltd. (RDY) & Lead Plaintiff Deadline: October 24, 2017
finance.yahoo.com - September 1 at 7:53 AM |
| DR. REDDY LOSS NOTICE: Rosen Law Firm Reminds Dr. Reddy’s Laboratories Ltd. Investors of Important Deadline in First Filed Class Action
finance.yahoo.com - September 1 at 7:53 AM |
| The Klein Law Firm Notifies Investors of Commencement of an Investigation Concerning Possible Violations of Federal Securities Laws by Dr. Reddy’s Laboratories Ltd. (RDY)
finance.yahoo.com - September 1 at 7:53 AM |
| Robbins Arroyo LLP: Dr. Reddy's Laboratories Limited (RDY) Misled Shareholders According to a Recently Filed Class Action
finance.yahoo.com - September 1 at 7:53 AM |
| SHAREHOLDER ALERT: Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit against Dr. Reddy’s Laboratories Limited
finance.yahoo.com - September 1 at 7:53 AM |
| CLSA Upgrades Dr. Reddy's Laboratories Ltd (RDY) to Outperform
www.americanbankingnews.com - August 31 at 12:34 PM |
Dr. Reddy's Laboratories Ltd (RDY) Chart for Wednesday, September, 20, 2017
